BRIEF-Bridgebio Study Shows 42% Cut In Total Number Of Acm And Recurrent Cvh Events Per Patient Observed Over 30-Mths With Acoramidis Treatment Versus Placebo

Reuters09-28 06:00

Sept 27 (Reuters) - BridgeBio Pharma Inc :

* BRIDGEBIO: ATTRIBUTE-CM STUDY SHOWS 42% CUT IN COMPOSITE ACM AND RECURRENT CVH EVENTS AT 30 MONTHS OBSERVED WITH ACORAMIDIS TREATMENT VERSUS PLACEBO

* BRIDGEBIO: STUDY SHOWS 42% CUT IN TOTAL NUMBER OF ACM AND RECURRENT CVH EVENTS PER PATIENT OBSERVED OVER 30-MTHS WITH ACORAMIDIS TREATMENT VERSUS PLACEBO

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470706563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-28 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470706563","market":"us","top_or_hot":-1,"title":"BRIEF-Bridgebio Study Shows 42% Cut In Total Number Of Acm And Recurrent Cvh Events Per Patient Observed Over 30-Mths With Acoramidis Treatment Versus Placebo","media":"Reuters","content":"<html><body><p>Sept 27 (Reuters) - BridgeBio Pharma Inc   :</p><p>   * BRIDGEBIO: ATTRIBUTE-CM STUDY SHOWS 42% CUT IN COMPOSITE ACM AND RECURRENT CVH EVENTS AT 30 MONTHS OBSERVED WITH ACORAMIDIS TREATMENT VERSUS PLACEBO</p><p>   * BRIDGEBIO: STUDY SHOWS 42% CUT IN TOTAL NUMBER OF ACM AND RECURRENT CVH EVENTS PER PATIENT OBSERVED OVER 30-MTHS WITH ACORAMIDIS TREATMENT VERSUS PLACEBO</p><p>((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bridgebio Study Shows 42% Cut In Total Number Of Acm And Recurrent Cvh Events Per Patient Observed Over 30-Mths With Acoramidis Treatment Versus Placebo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bridgebio Study Shows 42% Cut In Total Number Of Acm And Recurrent Cvh Events Per Patient Observed Over 30-Mths With Acoramidis Treatment Versus Placebo\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-28 06:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 27 (Reuters) - BridgeBio Pharma Inc   :   * BRIDGEBIO: ATTRIBUTE-CM STUDY SHOWS 42% CUT IN COMPOSITE ACM AND RECURRENT CVH EVENTS AT 30 MONTHS OBSERVED WITH ACORAMIDIS TREATMENT VERSUS PLACEBO   ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2470706563","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470706563","pubTimestamp":1727474402,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 27  - BridgeBio Pharma Inc   :   * BRIDGEBIO: ATTRIBUTE-CM STUDY SHOWS 42% CUT IN COMPOSITE ACM AND RECURRENT CVH EVENTS AT 30 MONTHS OBSERVED WITH ACORAMIDIS TREATMENT VERSUS PLACEBO   * BRIDGEBIO: STUDY SHOWS 42% CUT IN TOTAL NUMBER OF ACM AND RECURRENT CVH EVENTS PER PATIENT OBSERVED OVER 30-MTHS WITH ACORAMIDIS TREATMENT VERSUS PLACEBO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BBIO":"BridgeBio Pharma, Inc.","TSS":"Total System Services","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"BRIEF-Bridgebio研究显示，与安慰剂相比，Acoramidis治疗30个月内每例患者的Acm和复发性Cvh事件总数减少42%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSS":1,"BBIO":0.9},"content_text":"Sept 27 (Reuters) - BridgeBio Pharma Inc   :   * BRIDGEBIO: ATTRIBUTE-CM STUDY SHOWS 42% CUT IN COMPOSITE ACM AND RECURRENT CVH EVENTS AT 30 MONTHS OBSERVED WITH ACORAMIDIS TREATMENT VERSUS PLACEBO   * BRIDGEBIO: STUDY SHOWS 42% CUT IN TOTAL NUMBER OF ACM AND RECURRENT CVH EVENTS PER PATIENT OBSERVED OVER 30-MTHS WITH ACORAMIDIS TREATMENT VERSUS PLACEBO((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470706563"}